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Abstract Quinupristin–dalfopristin (Q-D) synergizes with
cefepime for the treatment of methicillin-resistant
Staphylococcus aureus (MRSA). Here, we studied whether
the synergism was restricted to MRSA and if it extended to
non-beta-lactam cell wall inhibitors or to other inhibitors of
protein synthesis. Three MRSA and two methicillin-
susceptible S. aureus (MSSA) strains were tested, including
an isogenic pair of mecA−/mecA+ S. aureus Newman. The
drug interactions were determined by fractional inhibitory
concentration (FIC) indices and population analysis profiles.
The antibacterial drugs that we used included beta-lactam
(cefepime) and non-beta-lactam cell wall inhibitors (D-cyclo-
serine, fosfomycin, vancomycin, teicoplanin), inhibitors of
protein synthesis (Q-D, erythromycin, chloramphenicol, tetra-
cycline, linezolid, fusidic acid), and polynucleotide inhibitors
(cotrimoxazole, ciprofloxacin). The addition of each protein
inhibitor to cefepime was synergistic (FIC ≤ 0.5) or additive
(FIC>0.5 but < 1) against MRSA, but mostly indifferent
against MSSA (FIC ≥ 1 but ≤4). This segregation was not
observed after adding cotrimoxazole or ciprofloxacin to cefe-
pime. Population analysis profiles were performed on plates in
the presence of increasing concentrations of the cell wall
inhibitors plus 0.25×minimum inhibitory concentration
(MIC) of Q-D. Cefepime combined with Q-D was synergistic
against MRSA, but D-cycloserine and glycopeptides were not.
Thus, the synergism was specific to beta-lactam antibiotics.
Moreover, the synergism was not lost against fem mutants,
indicating that it acted at another level. The restriction of the
beneficial effect to MRSA suggests that the functionality of
penicillin-binding protein 2A (PBP2A) was affected, either
directly or indirectly. Further studies are necessary in order to
provide a mechanism for this positive interaction.
Introduction
Staphylococcus aureus is a major pathogen that causes both
hospital-acquired and community-acquired infections. It is
also mastermind in developing resistance to antibacterial
agents [1]. It colonizes up to 20 % of the uninfected popu-
lation [2] and, thus, is frequently exposed to the antibiotics
used to treat infections caused by unrelated pathogens.
Therefore, it has a great chance of acquiring resistance to
any new antibacterial, even if the drug was originally tar-
geted against other bacteria.
Methicillin-resistant S. aureus (MRSA) is a paradigm of
this scenario. The loss of activity of beta-lactams against
penicillin-binding protein 2A (PBP2A)-positive strains
pushed the medical community to use numerous alternative
antibacterials; however, MRSA became resistant to all of
them [1]. Therefore, unless a number of new molecules with
no cross-resistance are made available for the treatment of
MRSA, staphylococci will develop resistance against each
consecutive new compound and add the resistance mecha-
nism to its existing multiresistance panoply [3]. As vanco-
mycin is still the preferred treatment used against MRSA, a
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continuous selective pressure in the clinical environment has
led to the emergence of vancomycin-intermediate S. aureus
(VISA) strains. These strains have a decreased susceptibility
to glycopeptides and are associated with vancomycin thera-
peutic failure [4]. New agents such as linezolid, tigecycline,
and daptomycin are now available for the treatment of
MRSA infections, but linezolid and tigecycline are only
bacteriostatic against S. aureus and are not approved for
invasive and difficult-to-treat infections such as endocardi-
tis. Moreover, resistance to these drugs is emerging [5, 6].
Producing entirely new molecules is a profound scientific
challenge [7]. Thus, it is also useful to explore the unex-
pected features of existing drugs. For instance, understand-
ing the mechanism of PBP2A-mediated resistance to beta-
lactams [1, 8] has set the rationale for the development of
beta-lactams with improved anti-PBP2A affinity, such as
ceftobiprole medocaril and ceftaroline fosamil [9, 10].
Alternatively, drug combinations can be useful by acting
in synergy or because their resistance mechanisms may be
mutually exclusive, as is the case for methicillin and lysos-
taphin in MRSA [11]. The advantages of combining existing
drugs are that their intrinsic toxicity is usually known and
the compounds are available for use. On the other hand, a
disadvantage is that the effects of drug combinations are
accomplished through complex interactions that are often
incompletely understood.
Recently, we and others have reported a synergism be-
tween the streptogramin quinupristin–dalfopristin (Q-D) and
beta-lactams in the treatment of MRSA both in vitro and in
rats with experimental endocarditis [12–14]. The combina-
tion of a low dose of Q-D with cefepime successfully cured
MRSA endocarditis in the animals, despite both being inef-
fective on their own [12]. In the present study, we tested in
vitro combinations of several classes of antibiotics with
cefepime, a beta-lactamase-resistant cephalosporin widely
used in the hospital setting. We show that the previously
observed positive interaction between Q-D and beta-lactams
is restricted to MRSA, does not translate to methicillin-
susceptible S. aureus (MSSA), and extends to other inhib-
itors of protein synthesis but not to mechanistically unrelat-
ed compounds.
Materials and methods
Microorganisms and growth conditions
The test organisms are described in Table 1. They included
the isogenic pair of MSSA and MRSA S. aureus Newman
mecA− and mecA+ strains [15], one multiresistant clinical
isolate of MSSA (strain P7142) [16], the homogeneously
methicillin-resistant MRSA COL strain [17], and the multi-
resistant clinical isolate MRSA P8 [18]. In certain experi-
ments, we also used three isogenic strains, including the
parent strain (MRSA BB270) [19] and two mutants lacking
the femB and femAB loci (MRSA BB815 and AS145, re-
spectively) [20, 21], which are implicated in the synthesis of
the pentaglycine cross-bridge (Table 1). The bacteria were
routinely grown at 35 °C in either tryptic soy broth (TSB;
Difco Laboratories, Detroit, MI) or tryptic soy agar (TSA;
Difco). Cation-supplemented Mueller–Hinton broth
(Difco) was used for the antibiotic-susceptibility tests
that were performed in liquid medium. All of the media
were supplemented with 2 % NaCl to increase the level
of expression of beta-lactam resistance genes by MRSA.
The stocks were kept at −70 °C in TSB supplemented
with 10 % (vol/vol) glycerol.
Antibiotics and chemicals
Cefepime was provided by Bristol-Myers Squibb AG
(Baar, Switzerland) and Q-D was provided by Aventis
Pharma AG (Zürich, Switzerland). All of the other
drugs and chemicals were commercially available
products.
Susceptibility testing and antibiotic interactions
The minimum inhibitory concentrations (MICs) were deter-
mined by a standard broth macrodilution method [22], with
a final inoculum of 105 to 106colony-forming units
(CFU)/ml. The antibiotic interactions were assessed by the
checkerboard method in 96-well microtiter plates (Dynatech
Microtiter, Chantilly, VA), as previously described [23]. The
Table 1 Strains used in this
study Strain Origin PBP2A Main resistance profile Reference
P7142 Parent − MSSA, CMLSB
r, Cmr, Tcr [16]
COL Parent + MRSA, Tcr [17]
P8 Parent + MRSA, CMLSB
r, Cmr, Tcr, Gmr [18]
Newman Parent − MSSA [15]
Newman mecA+ Newman mecA + MRSA [15]
BB270 Parent + MRSA [19]
BB815 BB270 ΔfemB + MSSA, Emr [20]
AS145 BB270 ΔfemAB + MSSA, Tcr [21]
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wells were filled with 100 μl of media containing
twofold serial dilutions of each of the test antibiotics
and inoculated with 105CFU/ml of bacteria (final con-
centration) from a logarithmic-phase culture; the plates
were then incubated for 24 h at 35 °C before visible
bacterial growth was determined. The fractional inhibi-
tory concentration (FIC) indices were interpreted as
follows: ≤0.5 for drug synergism, >0.5 but <1 for ad-
dition, ≥1 but ≤4 for indifference, and >4 for antago-
nism. For each antibiotic combination, the experiment
was performed in triplicate, and the lower of the FIC
index values is presented.
Population analysis profiles
The phenotypic expression of cefepime resistance was
determined by spreading a large bacterial inoculum
(≥109 CFU), as well as the appropriate dilutions, onto
NaCl-supplemented agar plates containing twofold serial
dilutions of the drug [24]. In certain experiments, the
plates were supplemented with a constant subinhibitory
concentration (0.25×MIC) of a partner drug [12]. The
numbers of colonies growing on the plates were enu-
merated after 48 h of incubation at 35 °C. The results
are presented by plotting the numbers of colonies grow-
ing on the plates against the cefepime concentration of
the plates. The expression of resistance to non-beta-
lactam cell wall inhibitors (fosfomycin, D-cycloserine,
vancomycin, teicoplanin) was determined in a similar
fashion.
Results
Antibiotic susceptibility and FIC indices
The drug susceptibilities of the test organisms are presented
in Table 2.
The positive or negative interactions between various
antibiotics were first determined by FIC indices. The drugs
included the beta-lactam cefepime, inhibitors of protein
synthesis, and inhibitors of nucleic acid synthesis and as-
sembly. Figure 1a depicts the results of combining cefepime
with the protein inhibitors. Most of these combinations
interacted positively against MRSA, as demonstrated by
the presence of synergism (FIC ≤ 0.5) in 14/18 (78 %) of
the cases and addition (FIC>0.5 but < 1) in 4/18 (22 %) of
the cases. In contrast, these combinations were only additive
(FIC>0.5 but < 1) or indifferent (FIC ≥ 1 but ≤ 4) against
the two MSSA isolates. This MRSA–MSSA dichotomy was
clearly apparent in the mecA− and mecA+ versions of S.
aureus Newman (Fig. 1a), suggesting that the presence of
PBP2A was involved.
To test whether this mecA-related difference was also a
property of other drug classes, the FIC experiments were
repeated with cefepime in combination with the two inhib-
itors of nucleic acid synthesis and assembly, cotrimoxazole
and ciprofloxacin. Figure 1b indicates that these combina-
tions were not more active against MRSA than MSSA.
Hence, the sensitization of MRSA to beta-lactams (in this
case, cefepime) [12] was not a conserved feature between all
of the drug classes.
Table 2 Minimum inhibitory
concentrations (MICs) of several
antibiotics for the five isolates
used to test the different antibi-
otic combinations
Antibiotics MICs in mg/L
Newman mecA− Newman mecA+ P7142 COL P8
Cell wall inhibitors
Cefepime 2 256 2 1,024 32
D-cycloserine 32 16 64 64 32
Fosfomycin 8 8 8 32 16
Vancomycin 2 2 1 2 1
Teicoplanin 1 2 0.5 1 0.25
Protein inhibitors
Q-D 0.5 0.5 0.25 0.25 0.125
Erythromycin 0.25 0.25 1,024 0.5 1,024
Chloramphenicol 8 4 64 8 16
Tetracycline 0.5 0.5 256 128 32
Linezolid 2 1 4 2 2
Fusidic acid 0.12 0.03 0.25 0.125 0.25
Nucleic acids inhibitors
Ciprofloxacin 0.25 0.125 0.25 0.125 0.25
Cotrimoxazole 2 2 0.25 1 1
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Population analysis profiles I: cefepime plus protein
inhibitors
The FIC indices are relative values that provide information
on the drug interactions independently of the bacterial re-
sistance phenotype (e.g., CMLSB
r, Cmr, Tcr, and Gmr for
MSSA 7142 and MRSA P8, as observed in Table 1). To
more quantitatively assess the changes in MICs due to the
partner compound, the drug combination experiments were
repeated in population analysis profiles. A series of agar
plates was prepared with increasing concentrations of
the drug to be tested plus a fixed subinhibitory concen-
tration (0.25×MIC) of the partner compound. The
mecA− and mecA+ S. aureus Newman strains were used
as the model organisms.
In the absence of an accompanying drug, the mecA+ S.
aureus Newman strain grew on plates containing up to
500 mg/L cefepime (Fig. 2a). In the presence of 0.25×
MIC of Q-D or erythromycin, the MIC of cefepime de-
creased by 10×and 5×, respectively, in the majority of the
cell population (99.9999 %). This positive effect is in ac-
cordance with the FIC indices depicted in Fig. 1a and is
supported by previous reports indicating that these drugs
could affect beta-lactam resistance in MRSA [12, 13]. In
comparison, the positive interaction was much less marked
in the mecA− S. aureus Newman strain (Fig. 2b), a result that
is also compatible with the FIC indices presented in Fig. 1a.
Thus, clinically achievable concentrations of Q-D and eryth-
romycin (0.125 and 0.062 mg/L, respectively) could affect
methicillin resistance in MRSA, but they barely affected
MSSA beta-lactam susceptibility.
When non-MLSB protein inhibitors were used (e.g.,
chloramphenicol, tetracycline, and linezolid), a similar—
yet less marked—positive effect was observed against the
mecA+ S. aureus Newman strain (Fig. 2c), whereas the
effect was, again, virtually non-existent against the mecA−
S. aureus Newman strain (Fig. 2d). In contrast, the DNA
inhibitor ciprofloxacin did not alter the MIC of cefepime for
either of the organisms (Fig. 2e, f).
The experiments were repeated to test the opposite set-
ting, i.e., whether the subinhibitory concentrations of cefe-
pime could affect the susceptibility of the bacteria to
inhibitors of protein synthesis. Cefepime was added to the
plates at a fixed subinhibitory concentration of 0.25×MIC
(125 and 0.5 mg/L for the mecA+ and mecA− S. aureus
Newman strains, respectively), whereas the inhibitors of
protein synthesis were added at increasing concentrations.
No beneficial or detrimental effects were observed with
either of the organisms (data not presented). Hence, minor
alterations of protein synthesis caused by low concentra-
tions of protein inhibitors could enhance the effect of the
beta-lactams, whereas marginal alterations of PBP function
by subinhibitory concentrations of the beta-lactams could
not enhance the effect of the protein synthesis inhibitors.
Population analysis profiles II: non-beta-lactam cell wall
inhibitors plus protein inhibitors
Because the inhibitors of protein synthesis, especially the
MLSB type, could decrease beta-lactam resistance in MRSA,
the question arose as to whether this effect was restricted to
beta-lactams or if non-beta-lactam inhibitors of cell wall syn-
thesis were also affected. Population analysis profiles were
repeated using the following: (i) D-cycloserine, as a drug acting
in the early synthesis of muropeptide precursors and before
PBP-mediated transpeptidation (Fig. 3), (ii) vancomycin and
0.25
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1.00
P8     COL    NW +           P7142   NW –
MRSA                            MSSA
b FIC indices
0.25
0.50
0.75
1.00
P8     COL    NW +           P7142   NW –
MRSA                            MSSA
a FIC indices
Fig. 1 Fractional inhibitory concentration (FIC) indices for cefepime
combined with other drugs, including a the inhibitors of protein syn-
thesis quinupristin–dalfopristin (black squares), erythromycin (white
squares), chloramphenicol (black triangles), tetracycline (white trian-
gles), linezolid (black circles), and fusidic acid (white circles) and b the
inhibitors of nucleic acid synthesis and assembly ciprofloxacin (black
diamonds) and cotrimoxazole (white diamonds). The tests were run
against the three methicillin-resistant Staphylococcus aureus (MRSA)
and two methicillin-susceptible S. aureus (MSSA) strains. The hori-
zontal line at 0.5 indicates the limit for synergism (FIC index ≤ 0.5).
The horizontal lines between 0.5 and 1 delineate the area of addition
(FIC index > 0.5 but < 1). The area above 1 indicates indifference (FIC
index ≥ 1 but ≤ 4). No antagonism between cefepime and any of the
other drugs tested was observed
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teicoplanin, as drugs acting after precursor maturation and
blocking the latest stages of cell wall assembly, and (iii) fosfo-
mycin, as a dual inhibitor of early precursor synthesis and
PBP2A expression [25] (Fig. 3).
Agar plates containing increasing concentrations of these
compounds were supplemented, or not, with 0.25×MIC of
Q-D and inoculated with the mecA+ and mecA− S. aureus
Newman strains as above (Fig. 4). Q-D marginally affected
the MIC of D-cycloserine for both organisms (Fig. 4a, b),
suggesting that the beneficial effect of Q-D with the cell
wall inhibitors must take place later in cell wall synthesis. At
the other extreme of cell wall synthesis, Q-D had no effect in
combination with vancomycin and teicoplanin on the two
bacteria (Fig. 4c–f), suggesting that the beneficial interac-
tion did not involve blockage of the precursor at the latest
steps in cell wall assembly. Finally, Q-D interacted positive-
ly with the dually active fosfomycin, but this interaction was
much more marked against the mecA+ (>10×decrease in the
MIC of fosfomycin) than against the mecA− (2×decrease in
the MIC of fosfomycin) S. aureus Newman strain (Fig. 4g,
h). Given that the D-cycloserine results indicated that the
early steps of precursor synthesis were not involved, and
because fosfomycin affects both early precursor assembly
and the expression of PBP2, 2A, and 4 [25] (Fig. 3), the
anti-MRSA effect of Q-D plus fosfomycin most likely op-
erated at the level of PBP functionality.
Effect of Q-D on the fem mutants
One critical feature of the function of PBP2A is its requirement
for pentaglycine-decorated stem peptides in the muropeptide
precursors (Fig. 3) [26]. The femA and femB genes ensure that
the pentaglycine side chains are added in a stepwise manner
[21]. To test whether the positive effect of the protein inhib-
itors could operate by altering the pentaglycine decorations,
the Q-D and cefepime FIC experiments were repeated against
the two fem mutants femB BB815 and femAB AS145, which
carry triglycine and monoglycine decorations instead of pen-
taglycine, respectively (Table 1), and their MRSA parent
BB270 [19–21]. The FIC indices were unaltered by the fem
mutations (0.6, 0.6, and 0.75 for the two mutants and the
parent, respectively), indicating that the positive effect of the
drug combination against the mecA+ staphylococci was an
addition, and not a synonym, of the fem mutations.
MRSA NewmanmecA+ MSSA Newman mecA-
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Fig. 2 Population analysis profiles for the isogenic strains of MRSA
Newman mecA+ (a, c, e) and MSSA Newman mecA− (b, d, f) plated on
increasing concentrations of cefepime in combination, or not, with a
subinhibitory concentration (0.25×MIC) of various partner drugs.
Large numbers of bacteria [≥ 109 colony-forming units (CFU)] and
the appropriate dilutions were plated, and the colonies were enumerat-
ed after 24 h of incubation at 35 °C and plotted against the
concentration of antibiotic. The details are as follows: cefepime alone
(+) or cefepime combined with a constant subinhibitory concentration
of quinupristin–dalfopristin (0.125 mg/L, black squares), erythromycin
(0.062 mg/L, white squares), chloramphenicol (2 mg/L, black trian-
gles), tetracycline (0.125 mg/L, white triangles), linezolid (0.25 mg/L,
black circles), or ciprofloxacin (0.062 mg/L, black diamonds)
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Discussion
These results highlight some salient features of the previ-
ously described synergism between Q-D and beta-lactam
against S. aureus [12–14]. First, the positive interaction
between the two drug classes was restricted to MRSA and
was much less potent in MSSA. This was clearly apparent in
the mecA+ and mecA− versions of S. aureus Newman and
was also observed across the five test isolates. Second, this
positive interaction extended to other inhibitors of protein
synthesis, although it was less marked with the non-MLSB
compounds. Third, this positive interaction did not extend to
mechanistically unrelated compounds such as DNA
inhibitors and non-beta-lactam inhibitors of cell wall
biosynthesis, except for fosfomycin. Together, these fea-
tures help to delineate, at least partially, the mechanism
of the drug interactions.
The restriction of the beneficial effect to MRSA indicates
that the inhibitors of protein synthesis affected the functional-
ity of PBP2A, either directly or indirectly. However, it does
not specify the mechanism by which the positive interaction
occurred. Our results obtained by combining the protein in-
hibitor Q-D with the non-beta-lactam cell wall inhibitors
suggested that the level of the interaction was between the
two extremes of the wall assembly line. At the early stage of
wall assembly, the positive effect of Q-D most likely occurred
after the addition of the D-ala-D-ala terminal to the muropep-
tide precursor, as no positive interaction was observed be-
tween Q-D and D-cycloserine. At the late stage of wall
assembly, Q-D did not synergize with direct blockers of the
precursors, such as glycopeptides, suggesting that the function
of PBP and/or the earlier steps were involved.
One possibility was that an interaction with the maturation
of muropeptide precursors was occurring, possibly at the level
of adding pentaglycine decorations to the stem peptides.
PBP2A requires pentaglycine-decorated precursors to be ef-
fective [26–28]. Indeed, mutations in the fem genes, which
block the addition of glycines to the precursors at various
levels, block the expression of methicillin resistance, regard-
less of the amount of PBP2A [17, 28, 29]. Protein inhibitors
could affect the fem pathway by decreasing the amounts of
glycine-adding enzymes, thus, formally replacing the fem
effect. If the protein inhibitors do affect the fem pathway, then
the Q-D plus beta-lactam synergism should be lost against the
fem mutants, while it should persist against the parent MRSA
strain. The experiments indicate that the beneficial effect of Q-
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Fig. 3 Principal steps of peptidoglycan assembly in S.aureus and
locations of inhibition by some cell wall inhibitors. Cell wall precur-
sors are synthesized in the cytoplasm from uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc) and transformed into uridine di-
phosphate N-acetylmuramic acid (UDP-MurNAc). This is followed
by the successive addition of one L-alanine (Ala), one D-isoglutamine
or isoglutamate (Glx), one L-lysine (Lys), and the dipeptide D-Ala-D-
Ala. The MurNAc pentapeptide is then linked to the plasma membrane
to form lipid I. A cytoplasmic transglycosylase adds a GlcNAc to the
MurNac moiety and five glycine (G) residues to the ε-NH2 terminal of
L-lysine, by the products of the fmhB, femA, and femB genes, to
complete the formation of lipid II. After membrane translocation, the
precursors are processed by the membrane penicillin-binding proteins
(PBPs) through the transglycosylation and transpeptidation steps. The
steps affected by beta-lactams, glycopeptides (vancomycin or teicopla-
nin), D-cycloserine, and fosfomycin are indicated within the figure.
Fosfomycin was also reported to decrease the expression of PBP2, 2A,
and 4 (not depicted in the figure) [25]
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D in combination with cefepime was identical in both the
parent and the femB and femAB mutant strains, as shown by
the FIC indices of 0.75, 0.6, and 0.6, respectively. Therefore,
the drug combination operated in addition to the fem muta-
tions and not instead of them.
Q-D had a positive interaction with fosfomycin, which
was consistent with recent reports of synergism between
fosfomycin and other protein synthesis inhibitors, such as
linezolid [30]. Fosfomycin disrupts the expression of PBP2,
2A, and 4. It is tempting to hypothesize that the expression
of the PBPs could also be altered, albeit in a different way,
following protein synthesis inhibition by Q-D or other pro-
tein inhibitors. This would explain the observed positive
interaction with fosfomycin, by complementary alterations
in the expression of the PBPs, as well as the beta-lactam
susceptibility restoration. A decrease in the amount of
PBP2A would be the simplest explanation for the observed
restoration of cefepime susceptibility in the tested MRSA
strains and the absence of this effect in the MSSA strains.
However, a decrease in PBP2 activity would also provide a
rationale for the MRSA-specific synergism observed.
Native S. aureus PBP2 is a class A PBP providing trans-
glycosylase activity for the glycan chain elongation step in
the cell wall building process. Hence, it is indispensable for
the functionality of the other purely transpeptidase PBPs,
including PBP2A. When MRSA are exposed to beta-
lactams, all of their transpeptidase sites are blocked except
for the low-affinity PBP2A site and the indispensable PBP2
transglycosylase site [31]. If this transglycosylase is further
inhibited by either decreasing its amount, as hypothesized
herein, or by specific drugs such as moenomycin, then
PBP2A can no longer function and the beta-lactams regain
their antibacterial activity. In MSSA, in contrast, the beta-
lactams need only to block the high-affinity native trans-
peptidases to block bacterial growth. This occurs at very low
drug concentrations, and additional inhibition of the trans-
glycosylase does not provide any additional effects. Thus,
the dichotomy of synergism between MRSA and MSSA
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Fig. 4 Population analysis
profiles of the isogenic strains
of MRSA Newman mecA+ (a,
c, e, g) and MSSA Newman
mecA− (b, d, f, h) plated on
increasing concentrations of the
non-beta-lactam cell wall
inhibitors D-cycloserine (white
circles), vancomycin (white
triangles), teicoplanin (white
diamonds), or fosfomycin
(white squares) either alone
(open symbols and dashed
lines) or in combination with a
constant subinhibitory
concentration (0.125 mg/L) of
quinupristin–dalfopristin
(closed symbols and continuous
lines). The details are the same
as in Fig. 2
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could be explained by the hypotheses reported above.
Further investigations, including the simultaneous titration
of PBPs (mainly PBP2 and 2A) in the presence or absence
of Q-D or other protein synthesis inhibitors at subinhibitory
concentrations, would be required.
Several additional genes affecting methicillin resistance
could also be involved. These include glnR (femC), which is
responsible for glutamic acid amidation in precursor stem
peptides, glmM (femD), which is responsible for UDP-N-ace-
tylglucosamine biosynthesis, and murE (femF), which is re-
sponsible for lysine addition in precursor stem peptides [28].
Moreover, protein inhibitors such as chloramphenicol and tet-
racycline can inhibit the stringent response of Escherichia coli
and promote the assembly of an abnormally thickened cell wall
[32]. S. aureus can also undergo the stringent response [33],
and subinhibitory concentrations of Q-D have been shown to
induce cell wall thickening in this very organism [34].
Proteomic and DNA array analysis of S. aureus exposed
to cell wall inhibitors revealed an ample alteration in gene
expression through a phenomenon known as the cell-wall-
stress stimulon [35, 36]. Among the altered genes, the
expression of PBP2 was increased after induction of the
vraSR genes. A possible interference of Q-D (or other
protein inhibitors) with the physiological beta-lactam stress
response (e.g., the VraSR system) would be another indirect
rationale for the Q-D–beta-lactam effect.
Answering the numerous questions requires the addition-
al titration of gene expression by microarrays. While such
an approach is being attempted, the present observation
offers further characterization of the previously observed
anti-MRSA synergism between Q-D and the beta-lactams.
Moreover, this precedent with MRSA may provide the
rationale for testing this synergism using additional organ-
isms that resist beta-lactams via decreased PBP affinity,
including pneumococci and enterococci, as well as examin-
ing new combinations of bactericidal beta-lactams with the
new anti-MRSA protein inhibitors linezolid and tigecycline.
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